DRUG · Mapped RxNorm record
Eribulin Mesylate
Normalized identity: eribulin mesylateView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
NCT05833919
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Capecitabine
Normalized identity: capecitabineView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedSecond Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Metastatic Breast Cancerunresolved
Interventions
Eribulin MesylateDRUG · verified · RxNorm: eribulin mesylate
CapecitabineDRUG · verified · RxNorm: capecitabine
Sponsors & collaborators
Consorzio Oncotechlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05833919 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.